基线糖尿病视网膜病变严重程度量表评分对VIVID-DME和VISTA-DME研究中视力结局的影响
本研究为VIVID-DME和VISTA-DME两项试验的事后分析,按基线糖尿病视网膜病变严重程度量表(DRSS)评分≤43、47和≥53分将糖尿病黄斑水肿患者分组,比较玻璃体腔注射阿柏西普与激光治疗的效果。第100周时,阿柏西普组视力获益优于激光组,且DRSS评分改善≥2级的患者比例更高,结论为无论基线DRSS评分如何,阿柏西普治疗的功能结局均更优。
要点
- 第100周时,基线DRSS≤43、47和≥53分患者中,阿柏西普较激光的最小二乘均值视力差异分别为8.9、9.7和11.0个字母。
- DRSS评分改善≥2级的患者比例,阿柏西普组在基线DRSS≤43、47和≥53分者中分别为13%、25.8%和64.5%,激光组分别为5.9%、4.5%和28.4%。
- 结论认为无论基线DRSS评分如何,阿柏西普治疗的功能结局均更优,显示在不同基线视网膜病变水平下一致的治疗获益。
核心结论
- 无论基线DRSS评分如何,玻璃体腔注射阿柏西普治疗的患者功能结局均优于激光,显示在不同基线视网膜病变水平下一致的治疗获益。
研究设计与样本
- VIVID-DME和VISTA-DME研究的事后分析,纳入基于眼底照片有基线DRSS评分的糖尿病黄斑水肿患者共748例(≤43分n=301;47分n=153;≥53分n=294)。
- 患者随机接受玻璃体腔注射阿柏西普2 mg每4周一次(2q4)、阿柏西普2 mg在5次初始每月剂量后每8周一次(2q8),或基线黄斑激光光凝合并每次访视假注射;2q4和2q8组也进行合并分析。
主要发现
- 第100周时,校正基线最佳矫正视力后,阿柏西普较激光的最小二乘均值差异在基线DRSS≤43、47和≥53分患者中分别为8.9(95%CI 5.99至11.81)、9.7(95%CI 5.54至13.91)和11.0(95%CI 7.96至14.1)个字母。
- DRSS评分改善≥2级的患者比例,阿柏西普组 vs 激光组在基线DRSS≤43分者为13% vs 5.9%,47分者为25.8% vs 4.5%,≥53分者为64.5% vs 28.4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To evaluate intravitreal aflibercept versus laser in subgroups of patients with baseline Diabetic Retinopathy Severity Scale (DRSS) scores ≤43, 47, and ≥53 in VIVID-DME and VISTA-DME. METHODS: Patients with diabetic macular oedema were randomised to receive intravitreal aflibercept 2 mg every 4 weeks (2q4), intravitreal aflibercept 2 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline with sham injections at every visit. These post hoc analyses evaluate outcomes based on baseline DRSS scores in patients in the integrated dataset. The 2q4 and 2q8 treatment groups were also pooled. RESULTS: 748 patients had a baseline DRSS score based on fundus photographs (≤43, n=301; 47, n=153; ≥53, n=294). At week 100, the least squares mean difference between treatment groups (effect of intravitreal aflibercept above that of laser, adjusting for baseline best-corrected visual acuity) was 8.9 (95% CI 5.99 to 11.81), 9.7 (95% CI 5.54 to 13.91), and 11.0 (95% CI 7.96 to 14.1) letters in those with baseline DRSS scores ≤43, 47, and ≥53, respectively. The proportions of patients with ≥2 step DRSS score improvement were greater in the intravitreal aflibercept group versus laser, respectively, for those with baseline DRSS scores of ≤43 (13% vs 5.9%), 47 (25.8% vs 4.5%), and ≥53 (64.5% vs 28.4%). CONCLUSIONS: Regardless of baseline DRSS score, functional outcomes were superior in intravitreal aflibercept-treated patients, demonstrating consistent treatment benefit across various baseline levels of retinopathy. TRIAL REGISTRATION NUMBERS: NCT01331681 and NCT01363440, Post-results.
引用
- Staurenghi G, Feltgen N, Arnold JJ, et al. Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies. Br J Ophthalmol. 2017. PMID: 29051325. doi:10.1136/bjophthalmol-2017-310664
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。